Company: PRME
Filing Date: 2025-07-14
Form Type: DEF 14A
Source: 0001193125-25-158716
Chunk: 18

Company: Prime Medicine, Inc.
Filing Date: 2025-07-14
Form: DEF 14A
Chunk 18
---
 Repricing Date due to the previously scheduled departures of certain employees. The closing price of our common stock on The Nasdaq Global Market on that date was $2.47 per share.

|                                         |     | Range of        
 Exercise Prices 
 of Eligible     
 Options         |     |    Number of Shares 
 Underlying Eligible 
             Options |     |   Weighted Average 
 Exercise Prices of 
   Eligible Options |     |  Weighted Average 
 Remaining Term of 
  Eligible Options 
           (Years) |
| Current non-executive officer employees |     | $3.45 - $18.22  |     |           3,900,066 |     |              $9.14 |     |              7.85 |
| Current executive officers              |     | $3.67 - $18.22  |     |           3,426,401 |     |              $8.10 |     |              7.70 |
| Current non-employee directors          |     | $7.68 - $17.00  |     |             958,920 |     |             $10.67 |     |              8.38 |

Eligible Options Certain of our current employees (including our named executive officers) and non-employeedirectors hold Eligible Options that would potentially benefit from the Option Repricing, in each case subject to the terms and conditions described above under “Specifics of the Option Repricing.” The following table sets forth, with respect to the individuals and groups identified therein, the number of shares subject to Eligible Options and the weighted average exercise price of the Eligible Options, in each case, as of June 30, 2025, but excludes the number of shares underlying certain outstanding stock options granted under the Plans that will cease to be Eligible Options as of the Repricing Date due to the previously scheduled departures of certain employees.

| Name and Position                                      |     | Number of  
 Shares     
 Subject to 
 Eligible   
 Options    |           |     | Weighted       
 Average        
 Exercise Price 
 of Eligible    
 Options        |        |
| Named Executive Officers                               |     |            |           |     |                |        |
| Allan Reine, M.D. (1)                                  
 Chief Executive Officer and Director                   |     |            |   850,000 |     |                |  $6.80 |
| Jeremy Duffield